Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Sandro Pignata, Michael Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Cagatay Taskiran, Charles Anderson, Sakari Hietanen, Tashanna Myers, Radoslaw Madry, Lyndsay Willmott, Alain Lortholary, Jessica Thomes-Pepin, Carol Aghajanian, Carolyn McCourt, Ashley Stuckey, Xiaohua Wu, Shin Nishio, Larry J. Copeland, Yvette HeLuciana Molinero, Sheetal Patel, Yvonne G. Lin, Victor K. Khor, Kathleen N. Moore
Dive into the research topics of 'Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer'. Together they form a unique fingerprint.